Sarcoidosis is a multisystemic disease of unknown etiology characterized by the presence of
epithelioid granulomas without caseous necrosis in the organs involved. Sarcoidosis cutaneous
lesions can be severe. There is no recommendation for the treatment of cutaneous sarcoidosis.
A recent study highlights the potential efficacy of mTOR inhibitors in the treatment of
sarcoidosis granulomas. The hypothesis is that sirolimus could be effective for sarcoidosis
treatment, especially for cutaneous lesions.
The main objective of this study is to evaluate sirolimus efficacy on cutaneous sarcoidosis
of the face.
The main evaluation criteria is the percentage of patients with a significant clinical
response (relative decrease in "facial SASI" ≥ 25%) at week 16 of treatment.